What question did this study set out to answer?

To assess risk stratification in patients with residual triple-negative breast cancer after neoadjuvant therapy.

February 8, 2026Breast Cancer Research and Treatment2 citationsOpen Access

Refined risk stratification in residual triple-negative breast cancer after neoadjuvant therapy using residual cancer burden class and lymphovascular invasion

TLT. LeeSamsung Medical Center HLHyunwoo LeeSamsung Medical Center JJJeong Yun JangKonkuk University Medical Center

Key Points

To assess risk stratification in patients with residual triple-negative breast cancer after neoadjuvant therapy.
Analyzed residual cancer burden and lymphovascular invasion in patients.
Stratified patients into risk groups based on these factors.
Evaluated the variability of adjuvant treatment effects across risk groups.
Patients with different residual cancer burden classes showed varied responses to adjuvant treatments.
Lymphovascular invasion presence further refined these risk stratifications.
Tailored adjuvant treatment based on RCB and LVI may improve patient outcomes.

Abstract

Patients with residual TNBC can be stratified into risk groups based on LVI and RCB class. The effect of adjuvant treatment varied across these groups. This model may support more tailored adjuvant treatment decisions after NST.

KI fragen

Bookmark

View Full Paper